key: cord-1005564-z0pdvnbs authors: Gao, Zhao-wei; Wang, Xi; Lin, Fang; Dong, Ke title: The correlation between SARS-CoV-2 infection and rheumatic disease date: 2020-05-01 journal: Autoimmun Rev DOI: 10.1016/j.autrev.2020.102557 sha: 1c12ffd74015ea63e69776d51faa925f6986cea2 doc_id: 1005564 cord_uid: z0pdvnbs nan Indeed, It has been established that SARS-CoV-2 infection enhances the release of multiple cytokines, such as IL-1b, IFN-γ, TNF-α, IL-4, IL-10, IL-8, IL-9, IL-6, etc [2, 3] . Among these increased cytokines, there are both pro-inflammatory cytokines and anti-inflammatory cytokines, which suggested that the balance of immune response was undergoing a great test in patients with COVID-19. As we know, autoimmune tolerance is an important part of immune homeostasis, which could be destroyed by multiple reasons, including pathogen infections. The production of multiple auto-antibodies is an important marker of autoimmune tolerance deficiency which is one of a trigger for autoimmune disorder diseases. Kerr JR have showed that parvovirus B19 infection could give rise to production of a variety of auto-antibodies (such as anti-nuclear antibody, anti-dsDNA antibody, etc), and be a trigger for development of a diverse array of autoimmune diseases [4] . A recent study by Zhou Y and colleagues showed that autoimmune phenomena exist in some patients with COVID-19 [5] . Among 20 COVID-19 subjects, the prevalence of anti-52 kDa SSA/Ro antibody, anti-60 kDa SSA/Ro antibody and antinuclear antibody were 20%, 25% and 50% respectively, while multiple antibodies (i.e. Anti-Scl-70, Anti-Jo-1 antibody, Anticentromere B antibody, Anti-SmD1 antibody, Anti-SSB antibody, Anti-double-stranded DNA antibody, Anti-Streptolysin O antibody) were negative. We also test the rheumatoid factor (RF), anti-cyclic peptide containing citrulline antibodies (anti-CCP antibody) and Anti-Neutrophil Cytoplasmic Antibodies (ANCA), which are Rheumatology Alliance Global Registry [9] , which showed that 600 patients with rheumatic disease who have been diagnosed with COVID-19, including 144 RA patients and 72 SLE patients. According to the WHO situation report (29 Apr 2020, 2:00 CEST), COVID-19 has been confirmed in 2,959,929 patients (including 202,733 deaths). In the context of COVID-19 epidemic, due to the social isolation management measures are widely adopted and people's awareness of self -protection were improvement, the current data of rheumatic disease patients infected by SARS-CoV-2 might not reflect the real susceptibility of patients. However, the potential susceptibility of SARS-CoV-2 in SLE patients would be deduced from the following indirect evidences. First, in theory, due to the impairment of immune system and immunosuppressive related therapy, SLE patients are vulnerable to infection, including bacterial, viral and fungal. Danza [11] . Second, Sawalha AH et al's paper have shown a significant overexpres sion ACE2 in SLE CD4+ T cells [12] . As ACE2 is a functional receptor for the viral spike glycoprotein that allows the entry of SARS-CoV-2 into cells, the result hints the increasing SARS-CoV-2 susceptibility in SLE patients. Third, Wang PH have showed that IFN-γ could stimulate the expression of ACE2 in human primary keratinocytes [13] . Of Note, multiple inflammatory cytokines including IFN-γ and TNF-α, have been found to be increased in patients with COVID-19 [2] . These results suggested that SARS-CoV-2 can up-regulate its receptor ACE2 in human host to facilitate their infection and spread. We have detected the serum IFN-γ and TNF-α levels in SLE patients and healthy subjects by using Luminex multiplex assays. Compared with healthy controls, the serum IFN-γ levels were significant higher in SLE patients (Fig. 1A) . Combine with the evidence that up-regulation effect of IFN-γ on ACE2 expression, the increased levels of IFN-γ provide another evidence that SLE patients might be inherently more susceptible to SARS-CoV-2 infections. Forth, Haga S and colleagues have found that TNF-α-converting enzyme (TACE) facilitates SARS-Cov viral entry into cell, via inducing ACE2 ectodomain shedding, and the process is tightly coupled with TNF-α production [14] . Thus, TNF-α might be a marker for efficient viral entry. Of note, we have found the increased of serum TNF -α level in SLE patients (Fig. 1B) , which hint the TACE was active in SLE, and which hint the potential convenience for SARS-Cov-2 infection. patients. Up to date, there is no conclusive evidence of hydroxychloroquine can prevent SARS-CoV-2 infection [15] . And moreover, the therapeutic effect of hydroxychloroquine on COVID-19 remains in doubt. Although there was study have showed that hydroxychloroquine induces viral clearance after 6 days of treatment (70% of patients treated with hydroxychloroquine alone determined a viral clearance compared with 12. 5% of patients who did not receive hydroxychloroquine) [16] . However, recently, Magagnoli J's study showed that hydroxychloroquine didn't reduce the risk of mechanical ventilation in patients hospitalized with COVID-19 [17] . And moreover, the toxicity of hydroxychloroquine should not be ignored. Taken together, SLE patients might be more susceptibility to SARS-CoV-2. Thus, management of COVID-19 infection prevention in SLE patients should follow the prevention guidance from WHO. Hydroxychloroquine do not be used as an Preventive therapy for SARS-CoV-2 infection in SLE patients. The authors declared that there are no conflicts of interests. COVID-19 infection a nd rheumatoid a rthri tis : Fa rawa y, so close!. Autoi mmun Rev Clinical features of pa tients infected with 2019 novel corona vi rus in Wuhan Dys regula tion of i mmune response in pa tients with COVID-19 in Wuhan The rol e of parvovirus B19 i n the pathogenesis of a utoimmunity and a utoimmune disease Clini cal and Autoimmune Cha ra cteris ti cs of Severe a nd Cri ti cal Cases wi th COVID-19 Could Sars -corona vi rus-2 tri gger autoi mmune and/or autoinflammatory mechanisms in geneti cally predisposed subjects Pa tients wi th lupus a re not protected from COVID -19 SLE pa tients a re not immune to covi d-19: i mportance of sending the ri ght message a cross COVID-19 Gl obal Rheumatology Alliance Infection risk in sys temic lupus erythematosus pa tients : sus cepti bility fa ctors and preventi ve s trategies Risk of severe herpes simplex vi rus infecti on in s ystemic lupus erythema tosus : anal ysis of epi demiology a nd ri sk factors analysis in Ta iwan Epigenetic dys regulation of ACE2 and interferon-regulated genes might sugges t increased COVID-19 s usceptibility a nd severity i n lupus patients Increasing Hos t Cellula r Receptor-Angiotensin-Converting Enzyme 2 (ACE2) Expression by Corona vi rus may Fa ci litate 2019-nCoV Infection Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 i nduces TNF-alpha production and facilita tes vi ral entry To consider or not antimalarials as a prophyla ctic interventi on in the SARS-CoV-2 (Covi d-19) pandemic Hydroxychloroquine and azi thromyci n as a trea tment of COVID-19: resul ts of an open-label non-randomized cl inical tri al Outcomes of hydroxychloroquine usage in United Sta tes veterans hospitalized with Covi d-19